drugset / Trial / NCT07466940
A Clinical Study to Evaluate SM17 in Healthy Participants
RandomizedSequentialQuadruple-blindTreatment
Summary
This is a phase I study in Chinese healthy adult volunteer participants. It aims to evaluate the safety, tolerability, PK profile and immunogenicity of a single dose of SM17 SC in healthy Chinese adult participants. It also aims to evaluate the bioavailability of SM17 SC compared to SM17 IV.
Timeline
- Start
- 2025-10-14
- Primary completion
- 2026-02-03
- Completion
- 2026-02-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SM17 | Monoclonal antibody | 195 mg | Subcutaneous |
| Subject | SM17 | Monoclonal antibody | 390 mg | Subcutaneous |
| Subject | SM17 | Monoclonal antibody | 780 mg | Subcutaneous |